Aminoglycoside-induced translational read-through in disease: Overcoming nonsense mutations by pharmacogenetic therapy

Clinical Pharmacology and Therapeutics

Volumn 81, Issue 1, 2007, Pages 99-103

  Zingman, L V ^a,b   Park, S ^a,b   Olson, T M ^a,b   Alekseev, A E ^a,b   Terzic, A ^a,b  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC G 418; GENTAMICIN; PAROMOMYCIN;

ATAXIA TELANGIECTASIA; AUTOSOMAL RECESSIVE DISORDER; BLOOD CLOTTING FACTOR 7 DEFICIENCY; CONFORMATIONAL TRANSITION; CYSTIC FIBROSIS; CYSTINOSIS; DRUG BINDING; DRUG MECHANISM; DRUG PROTEIN BINDING; DUCHENNE MUSCULAR DYSTROPHY; GENE MUTATION; GENETIC DISORDER; GLYCOGEN STORAGE DISEASE TYPE 5; HAILEY HAILEY DISEASE; HEART ATRIUM FIBRILLATION; HEMOPHILIA; HETEROZYGOSITY LOSS; HUMAN; HURLER SYNDROME; MOLECULAR INTERACTION; NEPHROGENIC DIABETES INSIPIDUS; NEURONAL CEROID LIPOFUSCINOSIS; NONHUMAN; NONSENSE MUTATION; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; REVIEW; RNA CONFORMATION; RNA TRANSLATION; STOP CODON;

AMINOGLYCOSIDES; ANIMALS; CODON, NONSENSE; GENETIC DISEASES, INBORN; HUMANS; PHARMACOGENETICS; PROTEIN MODIFICATION, TRANSLATIONAL;

EID: 33845996905     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100012     Document Type: Review

References (35)

1. Nirenberg, M. The genetic code: Nobel lecture, http://nobelprize.org/ nobel_prizes/medicine/laureates/1968/press.html (1968).
2. Kellermayer, R. Translational readthrough induction of pathogenic nonsense mutations. Eur. J. Med. Genet. (2006).
3. Kusik, V. Mendelian Inheritance in Man: A Catalog of Human Genes and Genetic Disorders, (John Hopkins University Press: Baltimore, 1998).
4. Byers, P.H. Killing the messenger: new insights into nonsense-mediated mRNA decay. J. Clin. Invest. 109, 3-6 (2002).
5. Roberts, R.G., Gardner, R.J. & Bobrow, M. Searching for the 1 in 2,400,000: a review of dystrophin gene point mutations. Hum. Mutat. 4, 1-11 (1994).
6. Lukacs, G.L. & Durie, P.R. Pharmacologic approaches to correcting the basic defect in cystic fibrosis. N. Engl. J. Med. 349, 1401-1404 (2003).
7. Holbrook, J.A., Neu-Yilik, G., Hentze, M.W. & Kulozik, A.E. Nonsense-mediated decay approaches the clinic. Nat. Genet. 36, 801-808 (2004).
8. Luzzatto, L., Apirion, D. & Schlessinger, D. Mechanism of action of streptomycin in E. coli: interruption of the ribosome cycle at the initiation of protein synthesis. Proc. Natl. Acad. Sci. USA 60, 873-880 (1968).
9. Yoshizawa, S., Fourmy, D. & Puglisi, J.D. Structural origins of gentamicin antibiotic action. EMBO J. 17, 6437-6448 (1998).
10. Ogle, J.M. et al. Recognition of cognate transfer RNA by the 30S ribosomal subunit. Science 292, 897-902 (2001).
11. Recht, M.I., Douthwaite, S. & Puglisi, J.D. Basis for prokaryotic specificity of action of aminoglycoside antibiotics. EMBO J. 18, 3133-3138 (1999).
12. Burke, J.F. & Mogg, A.E. Suppression of a nonsense mutation in mammalian cells in vivo by the aminoglycoside antibiotics G-418 and paromomycin. Nucleic Acids Res. 13, 6265-6272 (1985).
13. Howard, M., Frizzell, R.A. & Bedwell, D.M. Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations. Nat. Med. 2, 467-469 (1996).
14. Bedwell, D.M. et al. Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line. Nat. Med. 3, 1280-1284 (1997).
15. Barton-Davis, E.R., Cordier, L., Shoturma, D.I., Leland, S.E. & Sweeney, H.L. Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice. J. Clin. Invest. 104, 375-381 (1999).
16. Keeling, K.M. & Bedwell, D.M. Clinically relevant aminoglycosides can suppress disease-associated premature stop mutations in the IDUA and P53 cDNAs in a mammalian translation system. J. Mol. Med. 80, 367-376 (2002).
17. Howard, M.T. et al. Sequence specificity of aminoglycoside-induced stop condon readthrough: potential implications for treatment of Duchenne muscular dystrophy. Ann. Neurol. 48, 164-169 (2000).
18. Bonetti, B., Fu, L., Moon, J. & Bedwell, D.M. The efficiency of translation termination is determined by a synergistic interplay between upstream and downstream sequences in Saccharomyces cerevisiae. J. Mol. Biol. 251, 334-345 (1995).
19. Namy, O., Hatin, I. & Rousset, J.P. Impact of the six nucleotides downstream of the stop codon on translation termination. EMBO Rep. 2, 787-793 (2001).
20. Clancy, J.P. et al. Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis. Am. J. Respir. Crit. Care Med. 163, 1683-1692 (2001).
21. Hein, L.K. et al. Alpha-L-iduronidase premature stop codons and potential read-through in mucopolysaccharidosis type I patients. J. Mol. Biol. 338, 453-462 (2004).
22. Lai, C.H. et al. Correction of ATM gene function by aminoglycoside-induced read-through of premature termination codons. Proc. Natl. Acad. Sci. USA 101, 15676-15681 (2004).
23. Helip-Wooley, A., Park, M.A., Lemons, R.M. & Thoene, J.G. Expression of CTNS alleles: subcellular localization and aminoglycoside correction in vitro. Mol. Genet. Metab. 75, 128-133 (2002).
24. Politano, L. et al. Gentamicin administration in Duchenne patients with premature stop codon. Preliminary results. Acta Myol. 22, 15-21 (2003).
25. Sleat, D.E., Sohar, I., Gin, R.M. & Lobel, P. Aminoglycoside-mediated suppression of nonsense mutations in late infantile neuronal ceroid lipofuscinosis. Eur. J. Paediatr. Neurol. 5, 57-62 (2001).
26. Wilschanski, M. et al. Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. N. Engl. J. Med. 349, 1433-1441 (2003).
27. James, P.D. et al. Aminoglycoside suppression of nonsense mutations in severe hemophilia. Blood 106, 3043-3048 (2005).
28. Pinotti, M. et al. Intracellular readthrough of nonsense mutations by aminoglycosides in coagulation factor VII. J. Thromb. Haemost. 4, 1308-1314 (2006).
29. Sangkuhl, K. et al. Aminoglycoside-mediated rescue of a disease-causing nonsense mutation in the V2 vasopressin receptor gene in vitro and in vivo. Hum. Mol. Genet. 13, 893-903 (2004).
30. Kellermayer, R., Szigeti, R., Keeling, K.M., Bedekovics, T. & Bedwell, D.M. Aminoglycosides as potential pharmacogenetic agents in the treatment of Hailey-Hailey disease. J. Invest. Dermatol. 126, 229-231 (2006).
31. Olson, T.M. et al. Kv1.5 channelopathy due to KCNA5 loss-of-function mutation causes human atrial fibrillation. Hum. Mol. Genet. 15, 2185-2191 (2006).
32. Porgpermdee, S. et al. Expression of SPCA1 (Hailey-Hailey disease gene product) in acantholytic dermatoses. J. Dermatol. Sci. 40, 137-140 (2005).
33. Schroers, A. et al. Gentamicin treatment in McArdle disease: failure to correct myophosphorylase deficiency. Neurology 66, 285-286 (2006).
34. Wagner, K.R. et al. Gentamicin treatment of Duchenne and Becker muscular dystrophy due to nonsense mutations. Ann. Neurol. 49, 706-711 (2001).
35. Xi, B., Guan, F. & Lawrence, D.S. Enhanced production of functional proteins from defective genes. J. Am. Chem. Soc. 126, 5660-5661 (2004).